Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Coffey

Showing results (471-480 of 512) with videos related to

Pageof 52
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society|May 4, 2021
Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's DiseaseThomas Kremer, Kirsten I Taylor, Juliane Siebourg-Polster, et al.
Annals of Neurology|December 25, 2024
Staged Screening Identifies People with Biomarkers Related to Neuronal Alpha-Synuclein DiseaseEthan G Brown, Lana M Chahine, Andrew Siderowf, et al.
The Journal of Clinical Investigation|August 31, 2023
Effects of AFQ056 on language learning in fragile X syndromeElizabeth Berry-Kravis, Leonard Abbeduto, Randi Hagerman, et al.
Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|April 21, 2012
Clinical features and racial/ethnic differences among the 3020 participants in the Secondary Prevention of Small Subcortical Strokes (SPS3) trialCarole L White, Jeff M Szychowski, Ana Roldan, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 25, 2018
Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative CohortTanya Simuni, Andrew Siderowf, Shirley Lasch, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 12, 2015
Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficitsNorbert Schuff, I-Wei Wu, Shannon Buckley, et al.
The Lancet. Neurology|November 4, 2019
Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional studyTanya Simuni, Liz Uribe, Hyunkeun Ryan Cho, et al.
International Journal of Radiation Oncology, Biology, Physics|September 22, 2024
Redefining Candidates for Deintensification in Locoregionally Advanced P16+ Oropharyngeal Cancer Based on Relative RiskRyan T Morse, Tyler J Nelson, Hannah C Liu, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 17, 2020
Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease ProgressionBrit Mollenhauer, Mohammed Dakna, Niels Kruse, et al.
Annals of Neurology|May 11, 2026
Recruitment Strategies across the Spectrum of Neuronal Synuclein DiseaseAndrew Siderowf, Laura E A Heathers, Kimberly Fabrizio, et al.
Pageof 52

Showing results (471-480 of 512) with videos related to

Sort By:
Pageof 52
Movement Disorders : Official Journal of the Movement Disorder Society|May 4, 2021
Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's DiseaseThomas Kremer, Kirsten I Taylor, Juliane Siebourg-Polster, et al.
Annals of Neurology|December 25, 2024
Staged Screening Identifies People with Biomarkers Related to Neuronal Alpha-Synuclein DiseaseEthan G Brown, Lana M Chahine, Andrew Siderowf, et al.
The Journal of Clinical Investigation|August 31, 2023
Effects of AFQ056 on language learning in fragile X syndromeElizabeth Berry-Kravis, Leonard Abbeduto, Randi Hagerman, et al.
Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|April 21, 2012
Clinical features and racial/ethnic differences among the 3020 participants in the Secondary Prevention of Small Subcortical Strokes (SPS3) trialCarole L White, Jeff M Szychowski, Ana Roldan, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 25, 2018
Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative CohortTanya Simuni, Andrew Siderowf, Shirley Lasch, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 12, 2015
Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficitsNorbert Schuff, I-Wei Wu, Shannon Buckley, et al.
The Lancet. Neurology|November 4, 2019
Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional studyTanya Simuni, Liz Uribe, Hyunkeun Ryan Cho, et al.
International Journal of Radiation Oncology, Biology, Physics|September 22, 2024
Redefining Candidates for Deintensification in Locoregionally Advanced P16+ Oropharyngeal Cancer Based on Relative RiskRyan T Morse, Tyler J Nelson, Hannah C Liu, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 17, 2020
Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease ProgressionBrit Mollenhauer, Mohammed Dakna, Niels Kruse, et al.
Annals of Neurology|May 11, 2026
Recruitment Strategies across the Spectrum of Neuronal Synuclein DiseaseAndrew Siderowf, Laura E A Heathers, Kimberly Fabrizio, et al.
Pageof 52